Weave Bio’s CEO and Co-founder, Brandon Rice, was recently featured on ISPE’s Future of Pharma podcast to discuss how The Weave Platform is transforming the way regulatory submissions are prepared.

In the episode, Brandon explains how our AI-native platform reduces the time it takes to generate submission-ready documents—from months of manual effort down to hours—while keeping human oversight at the center of the process. He shares insights on:

• The bottlenecks in traditional regulatory submissions and how automation helps overcome them
• The importance of accuracy, transparency, and human judgment in AI-assisted workflows
• How adoption of AI in pharma varies across company size and culture
• Global regulatory perspectives, including FDA’s growing interest in AI and EMA’s clearer guidance

Brandon emphasizes that AI is not replacing regulatory experts—it’s a powerful tool to help them work faster, with more focus on science and patients.

How is AI revolutionizing regulatory submissions in biotech and pharma? Find out in this episode of the AI in Action podcast, featuring Brandon Rice, Chief Product Officer at Weave.

Brandon shares insights on:
✔️ AI-powered automation in regulatory filings to accelerate drug approvals
✔️ Streamlining FDA submissions—cutting time and costs dramatically
✔️ Customer-driven product development for seamless compliance workflows
✔️ Expanding regulatory support from preclinical IND to clinical-stage submissions
✔️ Scaling AI-powered regulatory workbenches to support biotech, pharma, CROs, and consultants

Weave’s AI-native regulatory automation platform, AutoIND, is redefining how life sciences companies prepare, manage, and submit regulatory documents. From IND to BLA, NDA, and beyond, Weave is building an AI-driven regulatory workbench for the entire therapy lifecycle.

🎧 Listen now to learn how Weave is shaping the future of regulatory automation!

Watch